


PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>C07F 3/02, C07D 471/04</b>		A1	(11) International Publication Number: <b>WO 99/01459</b> (43) International Publication Date: 14 January 1999 (14.01.99)
(21) International Application Number: <b>PCT/EP98/03969</b> (22) International Filing Date: 29 June 1998 (29.06.98)		(81) Designated States: CA, CZ, FI, HU, IL, JP, SI, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(30) Priority Data: MI97A001544 30 June 1997 (30.06.97) IT		Published <i>With international search report.</i>	
(71) Applicant (for all designated States except US): ZAMBON GROUP S.p.A. [IT/IT]; Via della Chimica, 9, I-36100 Vicenza (IT).			
(72) Inventors; and (75) Inventors/Applicants (for US only): VILLA, Marco [IT/IT]; Viale Lunigiana, 10, I-20125 Milano (IT). ALLEGRI, Pietro [IT/IT]; Via S. Chiara, 27, I-36045 Lonigo (IT). ARRIGHI, Katiuscia [IT/IT]; Viale Brianza, 17, I-22060 Cabiate (IT). PAIOCCHI, Maurizio [IT/IT]; Via Valsesia, 86/B, I-20152 Milano (IT).			
(74) Agent: LONGONI, Alessandra; Zambon Group S.p.A., Corporate Patents & Trademarks Dept., Via Lillo del Duca, 10, I-20091 Bresso (IT).			
(54) Title: ORTHO-METALATION PROCESS FOR THE SYNTHESIS OF 2-SUBSTITUTED-1-(TETRAZOL-5-YL)BENZENES			
(57) Abstract <p>A process of direct metalation of phenyltetrazoles useful for preparing compounds of formula (II) intermediates for the synthesis of angiotensin II antagonists is described.</p>			
 (III)			

***FOR THE PURPOSES OF INFORMATION ONLY***

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

ORTHO-METALATION PROCESS                    FOR THE SYNTHESIS OF 2-SUBSTITUTED-1-(TETRAZOL-5-YL)BENZENES


---

5     The present invention relates to a process useful for the synthesis of 2-substituted-1-(tetrazol-5-yl)benzenes and, more particularly, it relates to a process of direct ortho-metalation of (tetrazol-5-yl)benzene useful for the preparation of 2-substituted-1-(tetrazol-5-yl)benzenes, well-known intermediates for angiotensin II antagonists.

10    The angiotensin II antagonists constitute a new therapeutic class, whose parent compound losartan (INN) has been recently launched on the pharmaceutical market as drug useful for the treatment of hypertension, anxiety, glaucoma, heart attack.

Most of the compounds belonging to the class of angiotensin II antagonists has a common biphenyltetrazolyl moiety.

15    Compounds such as the already mentioned losartan, candesartan, irbesartan, tasosartan and valsartan, to list the most known compounds of this therapeutic class, are all represented by the following general formula



20

in which A is an optionally substituted nitrogen containing heterocycle or an open amide residue.

In particular the A residue has the following meanings, for the different previously 25 identified angiotensin II antagonists:

losartan-                                        A= 2-butyl-4-chloro-5-hydroxymethyl-imidazol-1-yl

candesartan-                                    A= 2-ethoxy-7-carboxy-1H-benzimidazol-1-yl

irbesartan-                                      A= 2-butyl-1,3-diaza-spiro[4.4]non-1-en-4-on-3-yl

tasosartan-                                      A= 2,4-dimethyl -5,8-dihydro-6H-pyrido[2,3-d]pyrimidin-7-on-  
30    8-yl

valsartan-                                        A= (S)-N-(1-carboxy-2-methylprop-1-yl)-N-pentanoylamino

- 2 -

It is evident that one of the key intermediates useful in the synthesis of the compounds of formula I is represented by 2-substituted phenyltetrazole derivatives of formula

5



in which R is a hydrogen atom, a protective group or a salifying group and X is a halogen atom selected among chlorine, bromine and iodine.

10 The intermediates of formula II are used in a cross-coupling reaction with a suitable substituted phenyl derivative to obtain the biphenyl portion of the compounds of formula I.

In our knowledge, among the literature methods for the preparation of the compounds of formula II, only one method that involves a direct metalation, that is an exchange reaction between a hydrogen atom and a metal, is reported.

15 In particular this method is described in the U.S. patent No. 5,039,814 (Merck & Co. Inc.) and, in effect, it involves the ortho-lithiation of phenyltetrazole followed by a transmetalation reaction.

A disadvantage of this process is represented by the necessity to use organolithium  
20 compounds that require particular safety procedures to be used on a large scale, because of their high inflammability and reactivity.

The most common alternative to the direct metalation of phenyltetrazoles is the metalation of the corresponding 2-halo-substituted derivative, that is an exchange reaction between a halogen atom and a metal, as described, for example, in the  
25 European patent applications No. 550313 (Synthelabo) and No. 539086 (American Home Products Corp.).

It would be advantageous to prepare the phenyltetrazoles of formula II by direct metalation, avoiding the use of compounds that require particular safety procedures such as organolithium compounds.

- 3 -

Some methods for the direct metalation of activated organic compounds that do not involve lithium derivatives are well-known from the literature.

Von Adrian Marxer et al. in Helvetica Chimica Acta, 57(7), 1988-2000 (1974) 5 describe the use of ethylmagnesium bromide for the direct ortho-metallation of phenylpyrazoles with very good results.

Philip E. Eaton et al. in J. Am. Chem. Soc., 111(20), 8016-8018 (1989) reported the direct ortho-metallation of cubanes and of aromatic substrates by using an excess of a Hauser base, that is of a compound of formula  $R_2NMgBr$ .

10 Nevertheless our attempts to carry out the direct ortho-metallation of a phenyltetrazole to obtain a compound of formula II, following the methods described in the literature, were quite disappointing. In particular, using ethylmagnesium bromide no ortho-metallated product was formed whereas using a strong excess of a Hauser base the conversion was so low to make the process not practicable.

15 Now we have found that the compounds of formula II can be prepared by direct ortho-metallation of the corresponding phenyltetrazole without using organolithium compounds.

Therefore, object of the present invention is a process of direct ortho-metallation for the preparation of compounds of formula

20



in which

R is a hydrogen atom, a protective group or a salifying group and X is a halogen atom  
25 selected among chlorine, bromine and iodine;  
that involves the treatment of a compound of formula

30



- 4 -

in which R has the above reported meanings;

with a Grignard compound of formula



5 in which X has the above reported meanings and  $R_1$  is a straight or branched  $C_1\text{-}C_6$  alkyl group or a benzyl group;

in the presence of a catalytic amount of a secondary amine of formula



in which  $R_2$  and  $R_3$ , the same or different, are branched or cyclic  $C_3\text{-}C_6$  alkyl groups

10 or trialkylsilyl groups having from 1 to 3 carbon atoms in the alkyl moiety or  $R_2$  and  $R_3$ , together with the NH group form an optionally substituted cyclic amine.

The process object of the present invention is useful for the preparation of intermediates for the synthesis of angiotensin II antagonists.

15 The protective groups of the tetrazole moiety are those commonly used in the known syntheses of angiotensin II antagonists and they mainly consist of straight or branched  $C_1\text{-}C_6$  alkyl groups, optionally mono or poly substituted with aryl groups such as phenyl or pyridyl or with arylalkoxy groups, and of  $C_1\text{-}C_3$  alkoxy or alkylthio groups.

20 In the process object of the present invention the preferred protective group is tert-butyl.

Sodium and potassium ions are preferably used as salifying groups.

The alkylmagnesium halides of formula IV are well-known compounds.

Generally they are prepared from the corresponding alkyl halides by treatment with magnesium.

25 Preferably an ethylmagnesium halide prepared in situ, more preferably ethylmagnesium bromide, is used.

Generally the amount of the Grignard compound of formula IV is at least stoichiometric, preferably in slight excess compared to the phenyltetrazole of formula II, but amounts even lower than the stoichiometric one are successfully used.

- 5 -

Therefore the molar ratio compound IV: compound III is generally between 1:1 and 1.5:1, more preferably between 1.05:1 and 1.3:1.

The secondary amine of formula V usually has very bulky substituents linked to the  
5 NH group.

The amines of formula V are preferably those in which R<sub>2</sub> and R<sub>3</sub> are branched or cyclic C<sub>3</sub>-C<sub>6</sub> alkyl groups or R<sub>2</sub> and R<sub>3</sub> together with the NH group form an optionally substituted cyclic amine.

Specific examples of amines having branched or cyclic C<sub>3</sub>-C<sub>6</sub> alkyl groups as R<sub>2</sub> and  
10 R<sub>3</sub> substituents are diisopropylamine, di-tert-butylamine, di-sec-butylamine, tert-butyl-iso-propylamine, di-cyclopentylamine and di-cyclohexylamine.

Preferred examples of amines of formula V wherein R<sub>2</sub> and R<sub>3</sub> together with the NH group form an optionally substituted cyclic amine comprises pyrrolidines, piperidines and morpholines, which are tetra-substituted at the two vicinal positions to the  
15 nitrogen, such as 2,2,6,6-tetramethylpiperidine and 2,2,5,5-tetramethylpyrrolidine.

In particular the piperidine derivatives, in turn, can be further substituted at the 4 position by alkyl and alkoxy groups or by an oxo group protected as acetal.

Particularly preferred amines of formula V are 2,2,6,6-tetramethylpiperidine and diisopropylamine.

20 The amines of formula V are used in catalytic amount compared to the Grignard compound IV, that is in a molar amount smaller than the stoichiometric one.

Generally the molar ratio compound V: compound IV is between 0.01:1 and 0.5:1, more preferably between 0.05:1 and 0.2:1.

25 The direct ortho-metallation, object of the present invention, is carried out in a suitable solvent, usually ethers and their mixtures with aliphatic or aromatic hydrocarbons.

Preferably tetrahydrofuran, optionally in admixture with toluene, is used as solvent.

The temperature is not a critical parameter and, generally, it is between room and reflux temperature.

Preferably it is carried out at the reflux temperature.


- 6 -

Optionally the direct metalation reaction can be carried out by adding catalytic amount of metal salts too, with or without ligands.

The compounds of formula II, prepared according to the process object of the present invention, can be directly used in a cross-coupling reaction for the preparation of the biphenyltetrazolyl moiety of the compounds of formula I according to what previously reported.

Alternatively they can undergo a transmetalation reaction according to known techniques to obtain a compound of formula

10



in which R has the previously reported meanings; Y has the just reported meanings of  
15 X or is an OH, C<sub>1</sub>-C<sub>4</sub> alkoxy or C<sub>1</sub>-C<sub>4</sub> alkyl group; M is selected among Zn, B, Al,  
Cu and Sn and n is 1, 2 or 3 depending on the meaning of M.

Preferably the compounds of formula II obtained according to the process of the present invention are transmetalated to obtain the compounds of formula VI in which M is Zn and Y is chlorine, bromine or iodine.

20 The transmetalation is carried out by treating the Grignard compound with a zinc halide, generally ZnCl<sub>2</sub>.

The transmetalation reaction can be directly carried out by treating the reaction mixture, containing the Grignard compound II, with the suitable zinc halide.

25 The compound of formula VI is used for cross-coupling reactions as reported for the compounds II.

As previously reported the compounds of formula II, prepared according to the process object of the present invention, are useful as intermediates for the preparation of angiotensin II antagonists. In the present context the usefulness of the compounds of formula II is particularly exemplified in the preparation of the compound known as  
30 tasosartan according to the cross-coupling process described in the International patent application No. WO 96/40684 (American Home Products Corporation).

A preferred practical embodiment of the process of the present invention is the following:

Ethyl halide was added to a magnesium suspension in a suitable solvent to form the  
5 corresponding Grignard compound. After addition of a catalytic amount of 2,2,6,6-tetramethylpiperidine, the mixture was warmed and phenyl-tert-butyltetrazole was added.

At the end of the metalation reaction, that is when the evolution of ethane stopped,  
the resultant compound of formula II was directly treated with a zinc halide to obtain  
10 the corresponding compound of formula VI in which M=Zn, that was used for the cross-coupling reaction, without any isolation or purification.

In our knowledge the metalation process object of the present invention is the only method of direct metalation of phenyltetrazoles that does not use organolithium compounds.

15 Moreover the use of alkylmagnesium halides together with catalytic amount of a suitably bulky secondary amine is a method of direct metalation of aromatic compounds that, in our knowledge, has never been described in literature.

Actually, the prior art describes direct metalation reactions of compounds different from phenyltetrazoles or by simple reaction with ethylmagnesium bromide without  
20 any catalyst (see the above mentioned work of Von Adrian Marxer et al.) or by using an excess of Hauser bases ( see the above mentioned work of Philip E.Eaton et al.).

Nevertheless no method known from the literature is suitable for the direct metalation of phenyltetrazoles (see comparison examples).

It appears evident to the man skilled in the art that the process of direct metalation  
25 object of the present invention is an expedient alternative to the lithiation process described in the literature.

Apart from the remarkable advantage of avoiding the use of alkyl lithium, the process object of the present invention is particularly advantageous in its practical and industrial realisation because it does not use low temperatures and the obtained crude

compounds of formula II can be used either directly in the subsequent cross-coupling reaction or in the transmetalation reaction without any isolation or purification.

With the aim to better illustrate the present invention, the following examples are now  
5 given:

#### Example 1

Ethylbromide (5.5 g; 50 mmol) was dropped into a stirred suspension of magnesium turnings (1.2 g; 50 mmol) in tetrahydrofuran (25 ml), at 25°C under inert atmosphere, keeping the temperature below 60°C. At the end of the addition, the mixture was  
10 further stirred for 30 minutes at 60°C; then 2,2,6,6-tetramethylpiperidine (0.72 g; 5 mmol) was added and it was refluxed (73°C) for 1 hour. Phenyl-tert-butyltetrazole (8.1 g; 40 mmol) was added and the mixture was refluxed, under stirring, for 18 hours (altogether about 1000 ml of gas were evolved). Analysing a sample, after quenching  
15 with CH<sub>3</sub>OD for <sup>1</sup>H-NMR, the residual phenyl-tert-butyltetrazole was <5% of the starting amount.

The red-orange solution of tert-butylphenyltetrazolylmagnesium bromide (40 theoretical mmol) was cooled at 70°C and was added (the possible residual magnesium can be eliminated by settling) to a suspension of anhydrous zinc chloride (10.4 g; 76.2 mmol) in toluene (30 ml) during 15 minutes. The suspension was  
20 warmed at 60°C for 1 hour. 8-[(4-Bromophenyl)methyl]-5,8-dihydro-2,4-dimethyl-pyrido[2,3-d]pyrimidin-7(6H)-one (10.4 g; 30 mmol), palladium acetate (0.1 g; 0.44 mmol) and triphenylphosphine (0.35 g; 1.33 mmol) were added and the mixture was kept at 60°C for 24 hours. The suspension was cooled at 25°C; water (15 ml) and acetic acid (0.9 g) were added. The two phases were separated and the organic one  
25 was washed with water (10 ml) and evaporated to dryness under vacuum.

The residue, analysed by HPLC analysis, contains:

coupling product: 9.48 g (20.3 mmol)

starting material: 1.24 g (3.6 mmol)

#### Example 2

- 9 -

Ethylbromide (2.2 g; 20 mmol) was added dropwise to a stirred suspension of magnesium turnings (0.48 g; 20 mmol) in tetrahydrofuran (10 ml), at 25°C under inert atmosphere, keeping the temperature below 60°C. At the end of the addition, the  
5 mixture was stirred for 30 minutes; then 2,2,6,6-tetramethylpiperidine (0.29 g; 2 mmol) was added and it was refluxed (73°C) for 1 hour. At the temperature of 65°C, phenyltetrazole sodium salt (2.7 g; 16 mmol), in tetrahydrofuran (10 ml), was added in about 15 minutes. The mixture was kept under stirring, at 65°C, for 18 hours. It was cooled at 60°C, anhydrous zinc chloride (4.15 g; 30 mmol) was added in portions  
10 during 15 minutes and afterwards 8-[(4-bromophenyl)methyl]-5,8-dihydro-2,4-dimethyl-pyrido[2,3-d]pyrimidin-7(6H)-one (4.15 g; 12 mmol), palladium acetate (0.04 g; 0.18 mmol) and triphenylphosphine (0.142 g; 0.54 mmol) were added. The mixture was kept under stirring at 60°C for 24 hours.

The mixture, analysed by HPLC analysis, contains:  
15 coupling product: 2.99 g (7.3 mmol)  
starting material : 1.5 g (4.6 mmol)

#### Example 3

Ethylbromide (2.2 g; 20 mmol) was added dropwise to a stirred suspension of magnesium (0.488 g; 20 mmol) in tetrahydrofuran (10 ml), at 25°C under inert  
20 atmosphere, keeping the temperature below 60°C. The mixture was kept under stirring for 30 minutes; then diisopropylamine (0.4 g; 4 mmol) was added and it was refluxed (73°C) for 1 hour. Phenyl-tert-butyltetrazole (3.2 g; 16 mmol) was added and it was refluxed (73°C) for 28 hours.

The <sup>1</sup>H-NMR analysis pointed out the presence of about 80% of ortho-metalled  
25 product.

#### Example 4

2,2,6,6-Tetramethylpiperidine (1.33 g; 9.43 mmol) was added to a 23% mixture of methylmagnesium chloride in THF (69.1 g; 213 mmol), warmed at reflux and under stirring. The mixture was kept under stirring for 10 minutes, then phenyl-tert-

- 10 -

butyltetrazole (38.1 g; 188 mmol) was added and it was refluxed, under stirring, for 45 hours.

The <sup>1</sup>H-NMR analysis of a sample pointed out the presence of about 88% of ortho-metalled product.

The mixture was cooled at 40°C, then tetrahydrofuran (48 ml), toluene (157 ml) and anhydrous zinc chloride (51 g; 375 mmol) were added, keeping the temperature under 60°C. The resultant suspension was kept under stirring at 60°C for 2 hours. 8-[(4-Bromophenyl)methyl]-5,8-dihydro-2,4-dimethyl-pyrido[2,3-d]pyrimidin-7(6H)-one

(45 g; 130 mmol), palladium acetate (0.44 g; 1.95 mmol) and triphenylphosphine (1.5 g; 5.8 mmol) were added and the mixture was kept at 60°C for 4 hours. The suspension was cooled at 25°C; water (90 ml) and acetic acid (15 ml) were added. The two phases were separated and the organic one was evaporated to dryness under vacuum.

15 The residue, analysed by HPLC analysis, contains:

coupling product: 55.6 g (119 mmol;  $\gamma = 91\%$ )

starting material: < 0.5%

#### Example 5

2,2,6,6-Tetramethylpiperidine (0.31 g; 2.21 mmol) was added to a 2 M mixture of 20 benzylmagnesium chloride in THF (24.4 ml; 49 mmol), warmed at reflux and under stirring. The mixture was kept under stirring for 10 minutes, then phenyl-tert-butyltetrazole (8.95 g; 44 mmol) was added and it was refluxed, under stirring, for 45 hours.

The <sup>1</sup>H-NMR analysis of a sample pointed out the presence of about 80% of ortho-metalled product.

#### Example 6

Ethylbromide (6.3 g; 58 mmol) was added dropwise to a stirred suspension of magnesium turnings (1.27 g; 52.5 mmol) in tetrahydrofuran (10 ml), at 25°C under inert atmosphere, keeping the temperature below 60°C. At the end of the addition, the 30 mixture was stirred at reflux temperature; then 2,2,6,6-tetramethylpiperidine (0.31 g;

- 11 -

2.21 mmol) was added and it was refluxed for 10 minutes. Phenyl-tert-butyltetrazole (8.95 g; 44 mmol) was added and the mixture was kept under stirring, at reflux, for 25 hours. The <sup>1</sup>H-NMR analysis of a sample pointed out the presence of about 79%  
5 of ortho-metalled product.

#### Example 7

Ethylbromide (39.2 g; 360 mmol) was added dropwise to a stirred suspension of magnesium turnings (9.1 g; 374 mmol) in tetrahydrofuran (180 ml), at 25°C under inert atmosphere, keeping the temperature below 60°C. At the end of the addition, the  
10 mixture was refluxed for 30 minutes under stirring; then 2,2,6,6-tetramethylpiperidine (2.23 g; 16 mmol) was added and it was refluxed for further 10 minutes. Phenyl-tert-  
butyltetrazole (129 g; 639 mmol) was added and the mixture was kept under stirring,  
at reflux, for 19 hours. It was then cooled at 40°C, toluene (330 ml) and anhydrous  
zinc chloride (81 g; 593 mmol) were added, keeping the temperature below 60°C.  
15 The suspension was kept under stirring at 60°C for 2 hours, then 8-[(4-  
bromophenyl)methyl]-5,8-dihydro-2,4-dimethyl-pyrido[2,3-d]pyrimidin-7(6H)-one  
(81 g; 234 mmol), palladium acetate (0.79 g; 3.5 mmol) and triphenylphosphine (2.8  
g; 10.6 mmol) were added. The mixture was kept under stirring at 60°C for 18 hours.  
The suspension was cooled at 25°C, then water (120 ml) and acetic acid (15 ml) were  
20 added. The phases were separated and the organic phase was evaporated under  
vacuum.

The residue, analysed by HPLC analysis, contains:

coupling product: 87.5 g (187 mmol, y = 80%)

starting material: lower than 0.5%

#### 25 Comparison example 1

Ethylbromide (2.2 g; 20 mmol) was added dropwise to a stirred suspension of magnesium turnings (0.48 g; 20 mmol) in tetrahydrofuran (10 ml), at 25°C under inert atmosphere, keeping the temperature below 60°C. The mixture was kept under stirring for 30 minutes; phenyl-tert-butyltetrazole (4.0 g; 20 mmol) was added and it

- 12 -

was refluxed (73°C) for 3 hours. There was no evolution of gas and the <sup>1</sup>H-NMR analysis did not detect any ortho-metalled product.

Comparison example 2

5 Ethylbromide (4.4 g; 40 mmol) was added dropwise to a stirred suspension of magnesium (0.96 g; 40 mmol) in tetrahydrofuran (20 ml), at 25°C under inert atmosphere, keeping the temperature below 60°C. At the end of the addition, the mixture was stirred for 30 minutes; then 2,2,6,6-tetramethylpiperidine (5.8 g; 40 mmol) was added and it was refluxed (73°C) for 2 hour until the evolution of gas  
10 stopped. Phenyl-tert-butyltetrazole (1.35 g; 6.6 mmol) was added and it was refluxed (73°C).

The course of the ortho-metalation reaction was evaluated by <sup>1</sup>H-NMR analysis, with the following results:

after 1.5 hours        56% of metalled product  
15 after 3.0 hours        60% of metalled product  
after 4.0 hours        58% of metalled product.

- 13 -

### CLAIMS

1) A process of direct ortho-metallation for the preparation of compounds of formula

5



in which

R is a hydrogen atom, a protective group or a salifying group and X is a halogen atom

10 selected among chlorine, bromine or iodine;

which comprises the treatment of a compound of formula

15



in which R has the above reported meanings;

with a Grignard compound of formula



20 in which X has the just reported meanings and  $R_1$  is a straight or branched  $C_1$ - $C_6$  alkyl group or a benzyl group;

in the presence of a catalytic amount of a secondary amine of formula




25 in which  $R_2$  and  $R_3$ , the same or different, are branched or cyclic  $C_3$ - $C_6$  alkyl groups or trialkylsilyl groups having from 1 to 3 carbon atoms in the alkyl moiety or  $R_2$  and  $R_3$  together with the NH group form an optionally substituted cyclic amine.

2) A process according to claim 1 in which the molar ratio compound IV: compound III is between 1:1 and 1.5:1.

3) A process according to claim 2 in which the molar ratio is between 1.05:1 and 30 1.3:1.

- 14 -

- 4) A process according to claims 1, 2 or 3 in which compound IV is an ethylmagnesium halide.
- 5) A process according to claim 4 in which compound IV is ethylmagnesium bromide.
- 5 6) A process according to claim 1 in which the molar ratio compound V : compound IV is between 0.01:1 and 0.5:1.
- 7) A process according to claim 6 in which the molar ratio is between 0.05:1 and 0.2:1.
- 8) A process according to claim 1 in which the compound V is selected among  
10 diisopropylamine, di-tert-butylamine, di-sec-butylamine, tert-butyl-iso-propylamine, di-cyclopentylamine, di-cyclohexylamine, 2,2,6,6-tetramethylpiperidine and 2,2,5,5,-tetramethylpyrrolidine.
- 9) A process according to claim 8 in which the compound V is selected between diisopropylamine and 2,2,6,6-tetramethylpiperidine.
- 15 10) A process for the preparation of compounds of formula I



- 20 that comprises a process of direct ortho-metallation according to claim 1.
- 11) A process according to claim 10 for the preparation of tasosartan.

# INTERNATIONAL SEARCH REPORT

Int. Jpn. Application No  
**PCT/EP 98/03969**

**A. CLASSIFICATION OF SUBJECT MATTER**  
 IPC 6 C07F3/02 C07D471/04

According to International Patent Classification(IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
**IPC 6 C07F C07D**

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 96 40684 A (AMERICAN HOME PRODUCTS CORPORATION) 19 December 1996 see the whole document ---	1-11
A	US 5 278 312 A (CHEKROUN, I. ET AL.) 11 January 1994 see the whole document ---	1-9
A	US 5 039 814 A (SHUMAN, R.F. ET AL.) 13 August 1991 cited in the application see Scheme I ---	1
A	EP 0 550 313 A (SYNTHELABO) 7 July 1993 cited in the application see page 4 "Schéma 2" ---	1, 10 -/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

\* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "Z" document member of the same patent family

Date of the actual completion of the international search

14 September 1998

Date of mailing of the international search report

21/09/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3018

Authorized officer

Rinkel, L

## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/EP 98/03969

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 539 086 A (AMERICAN HOME PRODUCTS CORPORATION) 28 April 1993 cited in the application see the whole document ----	1, 10
A	WO 94 03435 A (E.I. DU PONT DE NEMOURS AND COMPANY) 17 February 1994 see examples -----	1, 10

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

Inte .ional Application No

PCT/EP 98/03969

Patent document cited in search report	Publication date	Patent family member(s)			Publication date
WO 9640684	A 19-12-1996	US AU CZ EP	5760220 A 6090296 A 9703900 A 0846117 A		02-06-1998 30-12-1996 17-06-1998 10-06-1998
US 5278312	A 11-01-1994	FR AT CA DE DE EP FI JP US	2696746 A 162192 T 2108231 A 69316309 D 69316309 T 0593332 A 934468 A 6192240 A 5382672 A		15-04-1994 15-01-1998 13-04-1994 19-02-1998 20-08-1998 20-04-1994 13-04-1994 12-07-1994 17-01-1995
US 5039814	A 13-08-1991	AT CA CY DE DE DK EP ES GR HK JP JP LV LV PT	146461 T 2041620 A 1998 A 69123632 D 69123632 T 455423 T 0455423 A 2095907 T 3022107 T 59497 A 4225966 A 7017619 B 11893 A 11893 B 97528 A		15-01-1997 03-11-1991 05-12-1997 30-01-1997 15-05-1997 09-06-1997 06-11-1991 01-03-1997 31-03-1997 16-05-1997 14-08-1992 01-03-1995 20-12-1997 20-03-1998 31-01-1992
EP 550313	A 07-07-1993	FR FR CA JP US	2685697 A 2688503 A 2086364 A 5271205 A 5371233 A		02-07-1993 17-09-1993 01-07-1993 19-10-1993 06-12-1994
EP 539086	A 28-04-1993	GB US US	2265899 A 5149699 A 5256654 A		13-10-1993 22-09-1992 26-10-1993

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

International Application No

PCT/EP 98/03969

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
EP 539086	A	AT	161537 T	15-01-1998
		AU	653635 B	06-10-1994
		AU	2607992 A	29-04-1993
		CA	2080705 A	25-04-1993
		CN	1175414 A	11-03-1998
		DE	69223734 D	05-02-1998
		DE	69223734 T	16-04-1998
		DK	539086 T	02-02-1998
		ES	2111617 T	16-03-1998
		FI	924397 A	25-04-1993
		GR	3025926 T	30-04-1998
		HU	9500549 A	30-10-1995
		IL	103436 A	31-03-1996
		JP	5222039 A	31-08-1993
		LV	12047 A	20-05-1998
		NO	301275 B	06-10-1997
		SG	47626 A	17-04-1998
		CN	1072682 A	02-06-1993
		CZ	282491 B	16-07-1997
		US	5498776 A	12-03-1996
		ZA	9207569 A	05-04-1994
-----	-----	-----	-----	-----
WO 9403435	A	17-02-1994	US 5310929 A	10-05-1994
			AU 688735 B	19-03-1998
			AU 4790393 A	03-03-1994
			CA 2141692 A	17-02-1994
			CN 1090275 A	03-08-1994
			EP 0654027 A	24-05-1995
			FI 950485 A	03-02-1995
			JP 8500103 T	09-01-1996
			MX 9304787 A	31-01-1995
			PL 307309 A	15-05-1995
			SG 47108 A	20-03-1998
			SK 13195 A	11-07-1995
			ZA 9305693 A	06-02-1995
-----	-----	-----	-----	-----